NACE 64.30 in FR. Official registry identity, company-size evidence and a rounded indicative valuation range on one indexed company profile.
DEVELOPPEMENT PHARMA is shown here as a public net-asset reference from filed balance sheets. It is not an earnings-multiple valuation; owner or advisor data is needed for debt, asset quality, leases and marketability adjustments.
Based on official company-size informationCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
Each step adds evidence that narrows the range. Public filings are a starting point. Connected accounts, owner context and method review make the valuation more useful for real decisions.
Continue privately and connect your accounting data to make the graph more accurate.
Continue as ownerTrack the buying status below. If the owner opens a process, you can request a conversation and review the details before making an offer.
View buying statusThis is a public asset-reference range, not an earnings-multiple valuation or a final transaction value. More accuracy requires owner or advisor context.
DEVELOPPEMENT PHARMA's indicative range combines official company-size information with sector multiples. It publishes no midpoint, asking price, offer, or recommendation and only becomes company-specific after refinement with owner or advisor data.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
DEVELOPPEMENT PHARMA, a business in NACE sector 64.30, is registered at an address in France. The company was founded in 2021, incorporated as a 5470.
DEVELOPPEMENT PHARMA is listed in French National Business Register (RNE/INPI) under registry number 908526676. This profile consolidates official annual accounts into one indexable company dossier.
Companies in this NACE 64.30 band file annual accounts with INPI.
The most recently filed revenue (2025) stands at €10,000.
DEVELOPPEMENT PHARMA's public range combines official company-size information with sector multiples. It remains indicative and is not a midpoint, sale price, offer, or recommendation.
The most recent annual filing covers 2025 (period end 2025-05-31).
It is not a midpoint, asking price, offer, or recommendation; owner or advisor data is required for a company-specific appraisal.
Public regulator-filed figures across 4 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202531 May 2025 | €10,000 | - | €12,390,988 | €11,596,149 | - |
| 202431 May 2024 | - | - | €11,079,448 | €10,485,560 | - |
| 202331 May 2023 | - | - | €9,504,007 | €9,469,567 | - |
| 202231 May 2022 | - | - | €9,191,052 | €9,149,743 | - |
DEVELOPPEMENT PHARMA was founded in 2021 and is registered with French National Business Register (RNE/INPI), incorporated as a 5470.
DEVELOPPEMENT PHARMA is registered under NACE 64.30: NACE 64.30. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2025 (period end 2025-05-31), publicly available via French National Business Register (RNE/INPI).
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for DEVELOPPEMENT PHARMA may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
